16.07.2012 - German pharmaceutical and chemical company Bayer sells the business with controversially debated drug Trasylol. The privately-held Dutch pharma The Nordic Group receives the worldwide marketing rights - except the US-territory.
The purchase price for Trasylol was not specified. In late 2008, health authorities in Germany and the United States told Bayer to stop distributing the aprotinin drug anywhere else. The trypsin inhibitor, which accounted for about EUR150m in annual sales, was used for complicated heart and liver surgery to reduce blood loss. In February this year, however, the EMA lifted the sales stop. The study results leading to the market ban had been incorrect said the Committee for Human Medicinal Products (CHMP). This positive opinion is expected to be ratified by the European Commission later in 2012. In Canada, the marketing stop had already been lifted in 2011. The Nordic Group is a European pharmaceutical company in private hands. Nordic claims to grow at an annual average rate of 20 percent. The company's focus is on niche products for hospitals and medicines for rare diseases.
12.02.2016 The promise of the microbiome as the basis of new treatments has caught the attention of many. Now, UK biotherapeutics maker 4D pharma plc has padded its microbiome pipeline with the acquisition of Irish Tucana Health.
05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.
04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.
01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.
27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.
25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.
21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.